Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 02921: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer Including Immunotherapy Refractory Expansion Cohorts With and Without Pembrolizumab

99 years and younger
All genders
This Phase 1, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation and a dose expansion phase. **PENNSYLVANIA HOSPITAL …
Learn More

UPCC 07124 A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with

99 years and younger
All genders
This study will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who have developed resistance to adjuvant endocrine therapy. …
Learn More

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

99 years and younger
All genders
Evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.
Learn More

CONVERT-II

99 years and younger
All genders
This is a prospective, open-label, multi-center, single-arm study enrolling subjects with severe heterogeneous emphysema and collateral ventilation in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement …
Learn More

AK-US-001-0105

99 years and younger
All genders
The primary objective of this study is to evaluate the effect of EFX compared to placebo on achieving NASH resolution AND fibrosis regression in subjects with fibrosis stage 2 or 3 at Week 52. Subjects meeting the study's eligibility criteria will randomly assigned in a 1:1:1 ratio to 1 of …
Learn More

AK-US-001-0107

99 years and younger
All genders
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of EFX in subjects with noninvasively diagnosed NASH/NAFLD. Subjects will be dosed QW with EFX 50 mg or placebo for up to 52 weeks. The safety and tolerability of EFX will be assessed during the study …
Learn More

UPCC 07224 A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

99 years and younger
All genders
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel inhibitors of active, GTP-bound RAS (RAS[ON]), in combination with other anticancer therapies in patients with gastrointestinal solid tumors.
Learn More

UPCC 08924: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors

99 years and younger
All genders
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 06224: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

CVC-HCC

99 years and younger
All genders
The overarching goal of our Clinical Validation Center for Hepatocellular Carcinoma (CVC-HCC) is to develop a robust infrastructure that will support efficient validation of emerging HCC biomarkers. Our CVC-HCC will also conduct studies to validate novel blood and imaging biomarkers to improve risk stratification and early detection in patients with …
Learn More
801 - 810 of 930